Siduma Therapeutics, founded by innovator Dr. Craig Crews, is leveraging extensive heterobifunctional molecule expertise to build a new, disruptive therapeutic platform targeting disease causing proteins. Siduma has assembled an exceptional leadership team and board with deep expertise in platform and drug development as well as company building. The company has recently closed a series A financing round with industry-leading investors. Qualified candidates seeking a highly mission-driven and collaborative culture along with cutting edge science are encouraged to apply for our open roles.